Swedish Orphan Biovitrum AB (publ) (SOBIV.ST)
Oct 25 Rare-disease drug maker Swedish Orphan Biovitrum (Sobi) reported on Wednesday a bigger jump than expected in quarterly core profit, raised its profit and sales guidance, and said it planned to boost operations in North America.
* Alprolix approved for treatment of Hemofili B in Saudi Arabia. Source text for Eikon: Further company coverage: (Reporting By Johan Sennero)
* Swedish orphan biovitrum says sobi now expects total revenues for full year to be in range of sek 6,300 to 6,400 m (6,100-6,200)
* Swedish orphan biovitrum Q2 total revenue was SEK 1,639 mln (1,469)